The incidence is approximately 0.4% at doses up to 450mg daily, which sounds small until you realize that certain conditions dramatically increase this baseline risk
Not that this has not been demonstrated before but to my surprise the questions on thyroid tumors and GLP-1 RA keep coming especially from non-endocrinologists This was a huge study that included a total of 460,032 users of GLP-1RAs, 717,792 users of SGLT2is, 2,055,583 users of DPP-4is, and 1,119,868 users of SUs GLP-1RA exposure was not associated with an increased risk of thyroid tumors compared with SGLT2is, DPP-4is, or SUs (meta-analysis: GLP-1RA vs
Im Verkauf stehen sehr gut erhaltene GLP Impression FR1 als 6er-Set im Case aus dem Motion Mietpark
This information does not substitute for professional diagnosis and treatment